Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

1964
2025

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1987 1
1988 2
1989 3
1990 3
1991 4
1992 3
1993 2
1994 13
1995 21
1996 21
1997 30
1998 17
1999 12
2000 18
2001 19
2002 10
2003 14
2004 16
2005 21
2006 25
2007 19
2008 11
2009 16
2010 14
2011 13
2012 18
2013 13
2014 11
2015 15
2016 10
2017 14
2018 16
2019 9
2020 9
2021 9
2022 12
2023 5
2024 12
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

460 results

Results by year

Filters applied: . Clear all
Page 1
Multiple endocrine neoplasia type 2: A review.
Mathiesen JS, Effraimidis G, Rossing M, Rasmussen ÅK, Hoejberg L, Bastholt L, Godballe C, Oturai P, Feldt-Rasmussen U. Mathiesen JS, et al. Semin Cancer Biol. 2022 Feb;79:163-179. doi: 10.1016/j.semcancer.2021.03.035. Epub 2021 Apr 1. Semin Cancer Biol. 2022. PMID: 33812987 Review.
Multiple endocrine neoplasias are rare hereditary syndromes some of them with malignant potential. Multiple endocrine neoplasia type 2 (MEN 2) is an autosomal dominant hereditary cancer syndrome due to germline variants in the REarranged
Multiple endocrine neoplasias are rare hereditary syndromes some of them with malignant potential. Multiple endocrin
Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.
Wells SA Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, Lee N, Machens A, Moley JF, Pacini F, Raue F, Frank-Raue K, Robinson B, Rosenthal MS, Santoro M, Schlumberger M, Shah M, Waguespack SG; American Thyroid Association Guidelines Task Force on Medullary Thyroid Carcinoma. Wells SA Jr, et al. Thyroid. 2015 Jun;25(6):567-610. doi: 10.1089/thy.2014.0335. Thyroid. 2015. PMID: 25810047 Free PMC article. Review.
Somatostatin receptors: from signaling to clinical practice.
Theodoropoulou M, Stalla GK. Theodoropoulou M, et al. Front Neuroendocrinol. 2013 Aug;34(3):228-52. doi: 10.1016/j.yfrne.2013.07.005. Epub 2013 Jul 18. Front Neuroendocrinol. 2013. PMID: 23872332 Review.
Somatostatin is a peptide with a potent and broad antisecretory action, which makes it an invaluable drug target for the pharmacological management of pituitary adenomas and neuroendocrine tumors. Somatostatin receptors (SSTR1, 2A and B, 3, 4 and 5) belong to the G protein …
Somatostatin is a peptide with a potent and broad antisecretory action, which makes it an invaluable drug target for the pharmacological man …
Therapeutic implications of menin inhibition in acute leukemias.
Issa GC, Ravandi F, DiNardo CD, Jabbour E, Kantarjian HM, Andreeff M. Issa GC, et al. Leukemia. 2021 Sep;35(9):2482-2495. doi: 10.1038/s41375-021-01309-y. Epub 2021 Jun 15. Leukemia. 2021. PMID: 34131281 Review.
Menin has a tumor suppressor function in endocrine glands. Germline mutations in the gene encoding menin cause the multiple endocrine neoplasia type 1 (MEN1) syndrome, a hereditary condition associated with tumors of the endocrine glands. …
Menin has a tumor suppressor function in endocrine glands. Germline mutations in the gene encoding menin cause the multiple
Management of medullary carcinoma of the thyroid: a review.
Jayasinghe R, Basnayake O, Jayarajah U, Seneviratne S. Jayasinghe R, et al. J Int Med Res. 2022 Jul;50(7):3000605221110698. doi: 10.1177/03000605221110698. J Int Med Res. 2022. PMID: 35822284 Free PMC article. Review.
Although infrequent, the interest in this cancer exceeds its incidence owing to its distinctive features and its characteristic association with other endocrine tumors. Although the majority of MTCs are sporadic, hereditary varieties occur in isolation or as a part of m
Although infrequent, the interest in this cancer exceeds its incidence owing to its distinctive features and its characteristic association …
Multiple Endocrine Neoplasia Type 1, Type 2A, and Type 2B.
Greenberg LA. Greenberg LA. Prim Care. 2024 Sep;51(3):483-494. doi: 10.1016/j.pop.2024.03.006. Epub 2024 May 23. Prim Care. 2024. PMID: 39067973 Review.
Multiple endocrine neoplasia type 1 is a rare genetic neuroendocrine syndrome caused by over 1500 different germline mutations. ...Multiple endocrine neoplasia type 2A (MEN2A) and Multiple endocrine n
Multiple endocrine neoplasia type 1 is a rare genetic neuroendocrine syndrome caused by over 1500 different germ
Guidelines for diagnosis and therapy of MEN type 1 and type 2.
Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, Conte-Devolx B, Falchetti A, Gheri RG, Libroia A, Lips CJ, Lombardi G, Mannelli M, Pacini F, Ponder BA, Raue F, Skogseid B, Tamburrano G, Thakker RV, Thompson NW, Tomassetti P, Tonelli F, Wells SA Jr, Marx SJ. Brandi ML, et al. J Clin Endocrinol Metab. 2001 Dec;86(12):5658-71. doi: 10.1210/jcem.86.12.8070. J Clin Endocrinol Metab. 2001. PMID: 11739416 Review.
Multiple endocrine neoplasia.
White ML, Doherty GM. White ML, et al. Surg Oncol Clin N Am. 2008 Apr;17(2):439-59, x. doi: 10.1016/j.soc.2007.12.002. Surg Oncol Clin N Am. 2008. PMID: 18375361 Review.
Update on multiple endocrine neoplasia Type 1 and 2.
Al-Salameh A, Baudry C, Cohen R. Al-Salameh A, et al. Presse Med. 2018 Sep;47(9):722-731. doi: 10.1016/j.lpm.2018.03.005. Epub 2018 Jun 13. Presse Med. 2018. PMID: 29909163 Review.
Multiple endocrine neoplasia type 1 is a rare genetic syndrome, characterized by the co-occurrence, in the same individual or in related individuals of the same family, of hyperparathyroidism, duodenopancraetic neuroendocrine tumors, pituitary adenomas
Multiple endocrine neoplasia type 1 is a rare genetic syndrome, characterized by the co-occurrence, in the same
C-cell hyperplasia.
Guyétant S, Bléchet C, Saint-André JP. Guyétant S, et al. Ann Endocrinol (Paris). 2006 Jun;67(3):190-7. doi: 10.1016/s0003-4266(06)72585-9. Ann Endocrinol (Paris). 2006. PMID: 16840909 Review.
Neoplastic CCH is caused by a germline mutation of the RET protooncogene in a multiple endocrine neoplasia type 2 (MEN 2) syndrome. It progresses to MTC following a time line that depends on the RET mutation involved. ...
Neoplastic CCH is caused by a germline mutation of the RET protooncogene in a multiple endocrine neoplasia type
460 results